The For The Media website offers news releases for upcoming studies from The JAMA Network journals, PDFs of embargoed studies, and the weekly JAMA Report video.
LEARN MORE: About The JAMA Network Journals | For the Media FAQs

New from the JAMA Report

use this as template for single videos
Read the Video Script
Print

New Interferon-Free Medications Successfully Treat Hepatitis C In Patients With H-I-V

INTRO: Today there are more highly effective treatments for patients with H-I-V. However, these patients can also have higher rates of hepatitis C infection. Even though the H-I-V is well controlled, patients can still become very ill and, in some cases, even die from liver disease related to hepatitis C. A new study tested whether an interferon-free medication regimen would be effective in patients who have both H-I-V and hepatitis C infection. Catherine Dolf explains in this week’s JAMA Report.

VIDEO
B-ROLL
People walking on the street

AUDIO
VO
ALMOST 7 MILLION PEOPLE WORLDWIDE ARE INFECTED WITH BOTH H-I-V AND HEPATITIS C.

AUDIO
SOT/FULL Super@ :06 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:10
“Hepatitis C infects the liver and causes slowly progressive scarring. Now, H-I-V accelerates that scarring.”

VIDEO
B-ROLL
Graphic: Figure with liver becoming more and more scarred.
Dissolve in:
Live Failure
Liver Cancer
Cirrhosis
Death

AUDIO
VO
DAMAGE FROM THIS SCARRING CAN CAUSE LIVER FAILURE, LIVER CANCER, CIRRHOSIS AND EVEN DEATH IN H-I-V PATIENTS.

AUDIO
SOT/FULL Super@ :20 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:04
“They’re not going to die of their H-I-V they are going to die of their hepatitis C.”

VIDEO
B-ROLL
Graphic: Interferon syringe
Dissolve in:
Side Effects
HIV Patients Not Eligible for Therapy

AUDIO
VO
UNTIL RECENTLY, TREATING HEPATITIS C HAS INCLUDED INTERFERON INJECTIONS. HOWEVER, INTERFERON HAS BEEN LINKED TO A NUMBER OF SERIOUS SIDE EFFECTS AND MANY H-I-V PATIENTS ARE NOT ELIGIBLE FOR THAT THERAPY. DR. MARK SULKOWSKI FROM JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE AND CO-AUTHORS TREATED 211 PATIENTS WITH BOTH H-I-V AND HEPATITIS C INFECTIONS.

AUDIO
SOT/FULL Super@ :44
Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:24
“They were split between patients with the most common strain of Hepatitis C which is called genotype 1.The other patients had genotypes 2 and 3, those are less common. The patients were all doing very well from a standpoint of HIV. They were either on anti-retroviral therapy or not at risk to have any complications with that disease.”

(Video covering middle of bite: blood being put into vials)

VIDEO
B-ROLL
Medications, Sofosbuvir and Ribavirin

AUDIO
VO
ALL THE PATIENTS RECEIVED A COMBINATION OF THE INTERFERON FREE MEDICATIONS SOFOSBUVIR AND RIBAVIRIN, ORALLY, OVER A PERIOD OF 12 OR 24 WEEKS.

AUDIO
SOT/FULL Super@ 1:17 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:09
“For patients with the most common strain, genotype 1, treated for 24 weeks, we achieved a cure in 76 percent of that patient population.”

GXF FULL
JAMA COVER

AUDIO
VO
THE STUDY APPEARS IN JAMA, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION.

AUDIO
SOT/FULL Super@1:30 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:06
“More patients with genotype 2 and 3 achieved a cure. Those strains are a little bit easier to treat than genotype 1.

VIDEO
B-ROLL
Blood vials being put in centrifuge

AUDIO
VO
FOR A PATIENT TO BE CONSIDERED CURED, HEPATITIS C WAS NO LONGER DETECTED IN THE BLOOD, 12 WEEKS AFTER THE LAST DOSE OF MEDICATION.

AUDIO
SOT/FULL Super@1:44 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:09
“Interferon-free therapies appear to work just as well in this patient population as they do in patients with hepatitis C alone.”

VIDEO
B-ROLL
People walking on street

AUDIO
VO
CATHERINE DOLF, THE JAMA REPORT.

TAG:RESEARCHERS SAY FURTHER STUDIES OF THIS ORAL REGIMEN ARE NEEDED IN DIVERSE POPULATIONS OF COINFECTED PATIENTS.

INTRO: Today there are more highly effective treatments for patients with H-I-V. However, these patients can also have higher rates of hepatitis C infection. Even though the H-I-V is well controlled, patients can still become very ill and, in some cases, even die from liver disease related to hepatitis C. A new study tested whether an interferon-free medication regimen would be effective in patients who have both H-I-V and hepatitis C infection. Catherine Dolf explains in this week’s JAMA Report.

VIDEO
B-ROLL
People walking on the street

AUDIO
VO
ALMOST 7 MILLION PEOPLE WORLDWIDE ARE INFECTED WITH BOTH H-I-V AND HEPATITIS C.

AUDIO
SOT/FULL Super@ :06 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:10
“Hepatitis C infects the liver and causes slowly progressive scarring. Now, H-I-V accelerates that scarring.”

VIDEO
B-ROLL
Graphic: Figure with liver becoming more and more scarred.
Dissolve in:
Live Failure
Liver Cancer
Cirrhosis
Death

AUDIO
VO
DAMAGE FROM THIS SCARRING CAN CAUSE LIVER FAILURE, LIVER CANCER, CIRRHOSIS AND EVEN DEATH IN H-I-V PATIENTS.

AUDIO
SOT/FULL Super@ :20 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:04
“They’re not going to die of their H-I-V they are going to die of their hepatitis C.”

VIDEO
B-ROLL
Graphic: Interferon syringe
Dissolve in:
Side Effects
HIV Patients Not Eligible for Therapy

AUDIO
VO
UNTIL RECENTLY, TREATING HEPATITIS C HAS INCLUDED INTERFERON INJECTIONS. HOWEVER, INTERFERON HAS BEEN LINKED TO A NUMBER OF SERIOUS SIDE EFFECTS AND MANY H-I-V PATIENTS ARE NOT ELIGIBLE FOR THAT THERAPY. DR. MARK SULKOWSKI FROM JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE AND CO-AUTHORS TREATED 211 PATIENTS WITH BOTH H-I-V AND HEPATITIS C INFECTIONS.

AUDIO
SOT/FULL Super@ :44
Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:24
“They were split between patients with the most common strain of Hepatitis C which is called genotype 1.The other patients had genotypes 2 and 3, those are less common. The patients were all doing very well from a standpoint of HIV. They were either on anti-retroviral therapy or not at risk to have any complications with that disease.”

(Video covering middle of bite: blood being put into vials)

VIDEO
B-ROLL
Medications, Sofosbuvir and Ribavirin

AUDIO
VO
ALL THE PATIENTS RECEIVED A COMBINATION OF THE INTERFERON FREE MEDICATIONS SOFOSBUVIR AND RIBAVIRIN, ORALLY, OVER A PERIOD OF 12 OR 24 WEEKS.

AUDIO
SOT/FULL Super@ 1:17 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:09
“For patients with the most common strain, genotype 1, treated for 24 weeks, we achieved a cure in 76 percent of that patient population.”

GXF FULL
JAMA COVER

AUDIO
VO
THE STUDY APPEARS IN JAMA, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION.

AUDIO
SOT/FULL Super@1:30 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:06
“More patients with genotype 2 and 3 achieved a cure. Those strains are a little bit easier to treat than genotype 1.

VIDEO
B-ROLL
Blood vials being put in centrifuge

AUDIO
VO
FOR A PATIENT TO BE CONSIDERED CURED, HEPATITIS C WAS NO LONGER DETECTED IN THE BLOOD, 12 WEEKS AFTER THE LAST DOSE OF MEDICATION.

AUDIO
SOT/FULL Super@1:44 Mark S. Sulkowski, M.D., – Johns Hopkins University School of Medicine Runs:09
“Interferon-free therapies appear to work just as well in this patient population as they do in patients with hepatitis C alone.”

VIDEO
B-ROLL
People walking on street

AUDIO
VO
CATHERINE DOLF, THE JAMA REPORT.

TAG:RESEARCHERS SAY FURTHER STUDIES OF THIS ORAL REGIMEN ARE NEEDED IN DIVERSE POPULATIONS OF COINFECTED PATIENTS.

Recent News Releases

News releases are made freely available to the general public. View all Past Releases >

JAMA Internal Medicine

Releases For July 28, 2014

JAMA Neurology

Releases For July 28, 2014